AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4025156
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion of amrinone (200 micrograms/kg/hr for 30 minutes, 400 micrograms/kg/hr for 30 minutes and then 800 micrograms/kg/hr for 30 minutes)
Trial: 4025156
Drug: High-dose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusion of amrinone (800, 1,600 and 3,200 micrograms/kg/hr sequentially, each for 30 minutes)
Trial: 24906836
Drug: Ayurvedic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic drugs (Mauktikyukta Kamdudha and Mauktikyukta Praval Panchamruta) during chemotherapy (Arm 1)
Trial: 24906836
Drug: Ayurvedic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic drugs (Mauktikyukta Kamdudha and Mauktikyukta Praval Panchamruta) after chemotherapy (Arm 2)
Trial: 24906836
Drug: Suvarnabhasmadi formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvarnabhasmadi formulation in addition to MKD and MPP after chemotherapy (Arm 3)
Trial: 20334478
Drug: Erdosteine (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (triple therapy consisting of pantoprazole, amoxicillin, and clarithromycin plus erdosteine)
Trial: 20334478
Drug: Placebo (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (triple therapy plus placebo)
Trial: 18361800
Drug: Aprotinin (500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (500,000 IU after induction and repeat dose after chest closure)
Trial: 16418548
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology (60 minutes, twice a week for five weeks)
Trial: 10417464
Drug: suxamethonium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.1 mg.kg‐1 intravenously
Trial: 7473009
Drug: ePTFE membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePTFE membrane alone (G)
Trial: 7473009
Drug: ePTFE membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePTFE membrane plus root conditioning (G + D)
Trial: 7473009
Drug: ePTFE membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePTFE membrane plus root conditioning plus composite graft (G + D + B)
Trial: 27484436
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Trial: 27484436
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg/day or 17.5 mg/week) alone
Trial: 27484436
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with vitamin K2 and risedronate
Trial: 22534814
Drug: Pralatrexate 190
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate 190 mg/m on days 1 and 15 of a 28-day cycle
Trial: 17293707
Drug: Quetiapine addition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine addition to serotonin reuptake inhibitors
Trial: 11453610
Drug: Inhaled beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta agonists, theophylline, cromolyn, inhaled corticosteroids
Trial: 10938493
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (500-1000 mg) plus hypertonic saline solution (HSS) infusion (150 ml of 1.4-4.6% NaCl) b.i.d.
Trial: 10938493
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (500-1000 mg) as a bolus b.i.d. without HSS.
Trial: 8794422
Drug: Matrix transdermal
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix transdermal estradiol delivery system worn for 7 consecutive days
Trial: 8794422
Drug: Reservoir transdermal
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reservoir transdermal patch worn for 4 days followed by another patch for 3 days
Trial: 1536785
Drug: 5% 5-aminosalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-aminosalicylic acid (5-ASA) cream applied three times daily for up to 14 days
Trial: 1536785
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied three times daily for up to 14 days
Trial: 6391735
Drug: Oral mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mixed grass‐pollen vaccine
Trial: 30895694
Drug: Purslane seeds
RxNorm normalized name: Purslane
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purslane seeds (10 g/day) with low-calorie diet
Trial: 22672949
Drug: Routine medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical therapy
Trial: 18468831
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg single dose, intramuscular)
Trial: 12020525
Drug: Azithromycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1.5 g total dose over 5 days)
Trial: 12020525
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1.5 g total dose over 5 days)
Trial: 8949472
Drug: Written test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written test administered 1 month before and directly after the training
Trial: 26586096
Drug: F1.8 formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F1.8 formula (1.8 g protein/418.4 kJ)
Trial: 26586096
Drug: F2.7 formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F2.7 formula (2.7 g protein/418.4 kJ)
Trial: 24613908
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for at least 5 months
Trial: 12030948
Drug: Red pepper
RxNorm normalized name: Red pepper
DrugBank: Red pepper (DB14759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red pepper powder (2.5 g/day for 5 weeks)
Trial: 7294869
Drug: Topical paraffin
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical paraffin
Trial: 26091023
Drug: 3% Hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Hypertonic Saline (250 mL)
Trial: 26091023
Drug: 7.5% Hypertonic
RxNorm normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% Hypertonic Saline (250 mL)
Trial: 26091023
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's Solution (LRS) (250 mL)
Trial: 15978753
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen 0.625 mg/day (CEE 0.625 mg)
Trial: 15978753
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal estradiol 50 microg/day (tE2)
Trial: 15978753
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day (CEE 0.625 mg/MPA 2.5 mg)
Trial: 15978753
Drug: Oral 2
RxNorm normalized name: SYRINGE,ORAL 20ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 2 mg 17‐beta estradiol combined with 1 mg norethistrone acetate (E2/norethistrone)
Trial: 1893805
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc supplementation (zinc sulfate 600 mg/day)
Trial: 29140378
Drug: Implant-supported fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported fixed prosthesis (group 1)
Trial: 29140378
Drug: Implant-supported fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported fixed prosthesis (group 2)
Trial: 18156641
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of elemental iron/daily added to school meals (group A)
Trial: 18156641
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of elemental iron/daily added to school meals (group B)
Trial: 11682399
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg IM
Trial: 7929824
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 21.5 pmol/kg per min for 2.5 h during hyperinsulinemic-euglycemic clamp
Trial: 7929824
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control saline infusion (0.45% saline)
Trial: 29453433
Drug: Earlier Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier Oral Feeding Group (initiated at 30 weeks' PMA)
Trial: 29453433
Drug: Later Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later Oral Feeding Group (initiated at 33 weeks' PMA)
Trial: 27317358
Drug: Featback supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Featback supplemented with low-intensity (weekly) digital therapist support
Trial: 24289887
Drug: rhEPO (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (40,000 IU intravenously, twice a week for 5 weeks)
Trial: 16614713
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy with activities from 1000 to 6000 MBq
Trial: 16614713
Drug: First course
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First course of radioiodine therapy
Trial: 10856472
Drug: Pulsatile IV
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile IV GnRH (10-20 microgram/90 min) after GnRH‐agonist down‐regulation
Trial: 10856472
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (50-150 mg; cycle days 3-7)
Trial: 9173664
Drug: Mannitol and
RxNorm normalized name: Mannitol and sorbitol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol and low sodium solution
Trial: 9173664
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol and high sodium concentration solution
Trial: 9173664
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol and low sodium solution
Trial: 3031260
Drug: High phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High phosphorus intake (1.67 mmol/kg/d, 50 mg/kg/d)
Trial: 3031260
Drug: Moderate phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate phosphorus intake (1.34 mmol/kg/d, 40 mg/kg/d)
Trial: 3031260
Drug: Low phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low phosphorus intake (1.01 mmol/kg/d, 30 mg/kg/d)
Trial: 24739318
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg prednisone daily for 5 days
Trial: 9539190
Drug: Indole‐3-carbinol (13C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indole‐3-carbinol (13C), 400 mg for two months
Trial: 7961534
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (exposure in vivo and response prevention)
Trial: 7961534
Drug: Naturalistic behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturalistic behavior therapy
Trial: 31821098
Drug: Oxybutynin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin (0.2 mg/kg 3 times daily)
Trial: 31165710
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment group (ITG) - Big White Wall (BWW) intervention for 3 months
Trial: 31165710
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment group (DTG) - no intervention for 3 months
Trial: 31260124
Drug: Tranilast 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast 8% liposomal gel
Trial: 28825957
Drug: Placebo (tranilast‐free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tranilast‐free liposomal gel)
Trial: 26093951
Drug: Cisplatin-based chronotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chronotherapy (administered at 18:00)
Trial: 24282565
Drug: Mobile Teams
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile Teams (MTs) providing counseling, condoms, screening and treatment for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) infections; presumptive metronidazole treatment.
Trial: 21539680
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg daily
Trial: 18997675
Drug: BUP (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP (300 mg) + NAL (50 mg)
Trial: 12637255
Drug: Nandrolone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nandrolone (600 mg/wk) + Resistance Training (RT)
Trial: 12637255
Drug: Nandrolone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nandrolone (600 mg/wk)
Trial: 12637255
Drug: Oxandrolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (20 mg/day) + Placebo
Trial: 10539752
Drug: 10 microgram
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microgram Se as L-selenomethionine
Trial: 10539752
Drug: 20 microgram
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microgram Se as L-selenomethionine
Trial: 10539752
Drug: 30 microgram
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microgram Se as L-selenomethionine
Trial: 10539752
Drug: 40 microgram
RxNorm normalized name: Travoprost 40 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 microgram Se as L-selenomethionine
Trial: 28245835
Drug: Facilitation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitation of creams availability and continuous electronic monitoring of consumption with regular feedback on skin care performance.
Trial: 17940809
Drug: Nadroparin (2,850/3,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (2,850/3,800 U daily subcutaneous)
Trial: 12957685
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity in obese subjects
Trial: 12957685
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity in non-obese subjects
Trial: 8645511
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with prednisone for 6 weeks followed by alpha‐2a interferon (IFN) for 6 months (group A)
Trial: 8645511
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of prednisone and IFN (group B)
Trial: 1536049
Drug: Verapamil therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil therapy (120 mg thrice daily)
Trial: 1536049
Drug: Verapamil therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil therapy (360 mg daily)
Trial: 6678823
Drug: Domifen bromide
RxNorm normalized name: domiphen bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domifen bromide in combination with antibiotics
Trial: 27488183
Drug: Yam bean
RxNorm normalized name: WILD YAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yam bean root juice (500 ml)
Trial: 27488183
Drug: Guava fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guava fruit juice (500 ml)
Trial: 7560220
Drug: Water (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (500 ml)
Trial: 12909502
Drug: Subcutaneous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous unfractionated heparin (5000 IU b.i.d.) and aspirin (100 mg daily)
Trial: 11865427
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59
Trial: 11865427
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) followed by 2 doses of the subunit gB vaccine
Trial: 11865427
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of both vaccines administered concomitantly
Trial: 14726726
Drug: Methylphenidate (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (both doses)
Trial: 25887302
Drug: Occupational medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational medicine intervention
Trial: 24171490
Drug: Control (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (unfractionated or low-molecular-weight heparin with optional glycoprotein IIb/IIIa inhibitors)
Trial: 15382303
Drug: CMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT with surgery and chemotherapy
Trial: 26817912
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after chemotherapy
Trial: 9058513
Drug: Cyclic regimen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic regimen of interferon alpha‐2b (IFN‐alpha) at a dose of 10 MU/m2 body surface subcutaneously on 5 consecutive days every 4 weeks
Trial: 27616628
Drug: BT (36-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT (36-session group Internet behavioral weight control treatment)
Trial: 27616628
Drug: BT +
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT + MI (36-session group Internet behavioral weight control treatment + 6 individual MI chat sessions)
Trial: 21334858
Drug: Solution Focussed
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution Focussed Group Therapy
Trial: 18777606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of static and dynamic magnetic fields (PEMF) applied 4 hours/day for 2 months
Trial: 15636358
Drug: External Qi-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Qi-therapy (EQT)
Trial: 3481635
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg) during sodium repletion (100 mmol/day)
Trial: 3481635
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg) during sodium depletion (20 mmol/day)
Trial: 12393110
Drug: Propofol-ketamine (1-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-ketamine (1-1.5 mg/kg)
Trial: 7843782
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril once daily in the morning for 5 days
Trial: 2162692
Drug: Daily diary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily diary card during chemotherapy
Trial: 412877
Drug: Intramuscular meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meptazinol
Trial: 10541446
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg, vitamin E, 30 mg, beta‐carotene, 6 mg) and minerals (selenium, 100 microg, and zinc, 20 mg)
Trial: 10541446
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with antioxidant vitamins and minerals
Trial: 1684314
Drug: GHRH after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH after saline infusion (Day 2)
Trial: 1684314
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion followed by saline (Day 3)
Trial: 1684314
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Day 1)
Trial: 30002007
Drug: Best usual
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best usual primary care plus treatment with oseltamivir for 5 days
Trial: 27936189
Drug: Peppy comments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppy comments from attending physicians (e.g., 'Hope you have a quiet day!')
Trial: 20146365
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (intravenous ceftazidime and tobramycin)